Florida is currently home to 3757 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Miami, Tampa, Jacksonville and Orlando. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
A Study to Investigate the Safety and Pharmacological Effect of a Single Intravenous Infusion of Belantamab in Male and Female Participants Aged 18 to 75 With Autoimmune Disease
Recruiting
The goal of this clinical trial is to assess the safety and tolerability profile of belantamab. The study will also assess how the levels of belantamab change over time and body's reaction to it in participants with stable but active autoimmune disease.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
04/18/2025
Locations: GSK Investigational Site, Medley, Florida
Conditions: Autoimmune Diseases
RECOVER-SLEEP: Platform Protocol
Recruiting
The platform protocol is designed to be flexible so that it is suitable for a range of study settings and intervention types. Therefore, the platform protocol provides a general protocol structure that can be shared by multiple interventions and allows comparative analysis across the interventions. For example, objectives, measures, and endpoints are generalized in the platform protocol, but intervention-specific features are detailed in separate appendices. This platform protocol is a prospect... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/18/2025
Locations: University of Florida College of Medicine Jacksonville, Jacksonville, Florida
Conditions: Long COVID, Long COVID-19, Hypersomnia, Sleep Disturbance
A Study of BV-AVD in People With Bulky Hodgkin Lymphoma
Recruiting
The purpose of this study is to test whether BV-AVD is an effective treatment in people with early stage, bulky Hodgkin lymphoma that was recently diagnosed and who have not yet received any treatments for their disease. BV is a type of drug called an antibody-drug conjugate (ADC). ADCs are a substance made up of a monoclonal antibody chemically linked to a drug. Antibodies are proteins made by the immune system to fight infections and other possible harms to the body. The monoclonal antibody b... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/18/2025
Locations: University of Miami, Miami, Florida
Conditions: Hodgkin Lymphoma
Study of REM-422 in Patients With AML or Higher Risk MDS
Recruiting
The goal of this study is to determine the safety and antitumor effects of REM-422, a MYB mRNA degrader, in people with Higher Risk MDS and relapsed/refractory AML
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/18/2025
Locations: Moffitt Cancer Center, Tampa, Florida
Conditions: Myelodysplastic Syndromes, Higher Risk Myelodysplastic Syndromes, Acute Myeloid Leukemia, Acute Myeloid Leukemia Refractory
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
Recruiting
The purpose of this study is to evaluate the effectiveness and safety of Arlocabtagene Autoleucel (BMS-986393) in participants with relapsed or refractory multiple myeloma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/18/2025
Locations: Local Institution - 0062, Jacksonville, Florida
Conditions: Multiple Myeloma
A Study of the Efficacy and Safety of SP-624 in the Treatment of Adults With Major Depressive Disorder
Recruiting
This is a Phase 2B clinical study evaluating the effectiveness and safety of SP-624 as compared to placebo in the treatment of adults with Major Depressive Disorder.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
04/18/2025
Locations: Clinical Neuroscience Solutions, Jacksonville, Florida
Conditions: Major Depressive Disorder
Efficacy and Safety of Subcutaneous Dupilumab in Participants With Asthma/Asthmatic Wheeze Aged 2 to <6 Years (LIBERTY ASTHMA TREKIDS)
Recruiting
This is a parallel, Phase 3, 2-arm study to evaluate the efficacy and long-term safety of dupilumab treatment in children 2 to \<6 years of age with uncontrolled asthma and/or recurrent severe asthmatic wheeze. The study will be conducted in 2 parts. Part A will be a 52-week, randomized, double-blind, placebo-controlled study to assess the safety and efficacy of dupilumab in children aged 2 to \<6 years old with uncontrolled asthma and/or recurrent severe asthmatic wheeze. At the end of Part A,... Read More
Gender:
ALL
Ages:
Between 2 years and 5 years
Trial Updated:
04/18/2025
Locations: Allervie Clinical Research - Destin- Site Number : 8400016, Destin, Florida
Conditions: Wheezing, Asthma
A Study Evaluating Atezolizumab, With or Without Bevacizumab, in Patients With Unresectable Hepatocellular Carcinoma and Child-Pugh B7 and B8 Cirrhosis
Recruiting
The purpose of this study is to assess the safety and efficacy of atezolizumab and bevacizumab, or atezolizumab alone, as first-line treatment in participants with unresectable, locally advanced or metastatic hepatocellular carcinoma (HCC) with Child-Pugh B7 or B8 cirrhosis.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/18/2025
Locations: Orlando Health Inc., Orlando, Florida
Conditions: Hepatocellular Carcinoma
Evaluate Efficacy, Safety and Tolerability of JTT-861 in Subjects With Heart Failure With Reduced Ejection Fraction
Recruiting
This study will evaluate the efficacy, safety, tolerability and pharmacokinetics of JTT-861 administered once daily for 12 weeks in subjects with heart failure with reduced ejection fraction (HFrEF) who are on a stable, guideline-directed medical therapy for heart failure.
Gender:
ALL
Ages:
Between 30 years and 85 years
Trial Updated:
04/18/2025
Locations: Nature Coast Clinical Research, Crystal River, Florida
Conditions: Chronic Heart Failure
IVIG for Infection Prevention After CAR-T-Cell Therapy
Recruiting
This phase II trial compares the effects of immunoglobulin replacement therapy with a placebo for preventing infectious complications in patients receiving CD19 chimeric antigen receptor (CAR)-T cell therapy. Hypogammaglobulinemia is a common complication in patients who receive CD19 CAR-T cell therapy. This is a condition in which the level of immunoglobulins (antibodies) in the blood is low and the risk of infection is high. Immunoglobulin replacement therapy works by replacing the body's immu... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/18/2025
Locations: Moffitt Cancer Center, Tampa, Florida
Conditions: Hematologic Malignancies
Comparing Retreatment of 177Lu-DOTATATE PRRT Versus Everolimus in Patients With Metastatic Unresectable Midgut Neuroendocrine Tumors, NET RETREAT Trial
Recruiting
This phase II trial compares the effect of retreatment with 177Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) to the usual approach of treatment with everolimus in patients who have previously received 177Lu-DOTATATE for midgut neuroendocrine tumor (NET) that has spread from where it first started (primary site) to other places in the body (metastatic) and that cannot be removed by surgery (unresectable). PRRT is a type of radiation therapy for which a radioactive chemical is linked to... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/18/2025
Locations: UM Sylvester Comprehensive Cancer Center at Aventura, Aventura, Florida
Conditions: Metastatic Midgut Neuroendocrine Tumor, Unresectable Midgut Neuroendocrine Tumor, Metastatic Midgut Neuroendocrine Tumor G1, Metastatic Midgut Neuroendocrine Tumor G2
Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.
Recruiting
This is a Phase 3, multicenter, open-label, randomized, parallel group, treatment study to assess the efficacy and safety of lifileucel in combination with pembrolizumab compared with pembrolizumab alone in participants with untreated, unresectable or metastatic melanoma. Participants randomized to the pembrolizumab monotherapy arm who subsequently have a blinded independent central review- verified confirmed progressive disease (PD) will be offered lifileucel monotherapy in an optional crossove... Read More
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
04/18/2025
Locations: Orlando Health Cancer Institute, Orlando, Florida
Conditions: Metastatic Melanoma, Unresectable Melanoma, Melanoma